Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Ironwood Pharmaceuticals (IRWD) Enterprise Value (2016 - 2025)

Historic Enterprise Value for Ironwood Pharmaceuticals (IRWD) over the last 17 years, with Q3 2025 value amounting to -$140.4 million.

  • Ironwood Pharmaceuticals' Enterprise Value fell 5917.18% to -$140.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$140.4 million, marking a year-over-year decrease of 5917.18%. This contributed to the annual value of -$88.6 million for FY2024, which is 390.11% up from last year.
  • Latest data reveals that Ironwood Pharmaceuticals reported Enterprise Value of -$140.4 million as of Q3 2025, which was down 5917.18% from -$92.9 million recorded in Q2 2025.
  • In the past 5 years, Ironwood Pharmaceuticals' Enterprise Value ranged from a high of -$88.2 million in Q3 2024 and a low of -$741.6 million during Q1 2023
  • Moreover, its 5-year median value for Enterprise Value was -$177.2 million (2023), whereas its average is -$334.3 million.
  • Its Enterprise Value has fluctuated over the past 5 years, first tumbled by 9801.85% in 2021, then soared by 8598.42% in 2023.
  • Quarter analysis of 5 years shows Ironwood Pharmaceuticals' Enterprise Value stood at -$621.4 million in 2021, then decreased by 5.81% to -$657.5 million in 2022, then skyrocketed by 85.98% to -$92.2 million in 2023, then grew by 3.9% to -$88.6 million in 2024, then tumbled by 58.55% to -$140.4 million in 2025.
  • Its last three reported values are -$140.4 million in Q3 2025, -$92.9 million for Q2 2025, and -$108.5 million during Q1 2025.